Literature DB >> 2944859

Preferential tumor radiosensitization by analogs of nicotinamide and benzamide.

M R Horsman, D M Brown, M J Lemmon, J M Brown, W W Lee.   

Abstract

The effects of a range of different analogs of nicotinamide and benzamide on the X ray response of the EMT-6 tumor in vivo was investigated. Using an in vivo/in vitro survival assay, sensitization was seen at a dose of 2 mmole/kg for all but one of the analogs tested. The enhancement ratios (ER's) ranged from 1.0 to 1.5. Of particular interest were nicotinamide and SR-4350 which gave large ER's (1.5 and 1.4 respectively) at doses which were only about 12% of the LD50 values. In one normal tissue studied (skin reaction) a large single dose of nicotinamide (8 mmole/kg) only gave an ER of 1.1. These results will be discussed with reference to the mechanisms involved and the clinical implications.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2944859     DOI: 10.1016/0360-3016(86)90160-4

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  4 in total

1.  Modification of tumour radiation response in vivo by the benzamide analogue pyrazinamide.

Authors:  D J Chaplin; M J Trotter; K A Skov; M R Horsman
Journal:  Br J Cancer       Date:  1990-10       Impact factor: 7.640

2.  Metoclopramide enhances the effect of cisplatin on xenografted squamous cell carcinoma of the head and neck.

Authors:  E Kjellén; J Wennerberg; R Pero
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640

3.  Blood flow modification by nicotinamide and metoclopramide in mouse tumours growing in different sites.

Authors:  D G Hirst; B Joiner; V K Hirst
Journal:  Br J Cancer       Date:  1993-01       Impact factor: 7.640

4.  Enhancement of cyclophosphamide cytotoxicity in vivo by the benzamide analogue pyrazinamide.

Authors:  M R Horsman; D J Chaplin
Journal:  Br J Cancer       Date:  1994-04       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.